Product Images Losartan Potassium

This is a description of a medication called Losartan Potassium. Each film-coated tablet contains 100mg of the active ingredient, Losartan Potassium USP. The recommended dosage for adults is not given and is expected to be found in the accompanying circular. The medication must be stored between 15-30 degrees Celsius (59-86 degrees Fahrenheit) and protected from light. The manufacturer of the medication is Aembic Phamaceuticas Ltd, located in India, and the NDC code for the medication is 46708-447-30. The medication is available as a 30 tablet bottle, and there is a lot number and expiration date provided, which are not readable.*

This is a description for a medicine called Muroosse L ogartan Potassium. The NDC code for the medicine is 46708-445-30. The medicine comes in the form of tablets, and the recommended storage temperature is between 15°C to 30°C (59°F to 86°F). The tablets should be stored in a container with a tight lid to protect from light. The patient information leaflet should be attached while dispensing the medicine. The medicine is manufactured in Village Panelav, P.0. Tajpura, near Baska, Tauka: Halol, Alembic Panchmahal, Gujarat, India, under the license number G/959. The lot number and expiration date are not available.*

This is a prescription drug label for Losartan Potassium tablets containing 50mg of the active ingredient. The recommended adult dosage is not provided in the label and it advises referring to the accompanying circular. The tablets must be stored at a temperature range of 15°C to 30°C (59°F to 86°F) and protected from light. The label also identifies the manufacturer and includes the product's NDC and lot number.*

This is a clinical study report comparing the effectiveness of Atenolol and Losartan Potassium Tablets in reducing the risk of primary endpoints in patients. The report shows that in 9% of patients, the primary endpoint was achieved. The adjusted risk reduction was found to be 13% with a significance level of p=.021. The study was conducted over 66 months.*

The text is presenting the results of a study comparing the effectiveness of two drugs (Atenolol and Losartan Potassium Tablets) in preventing fatal and non-fatal stroke. The adjusted risk reduction for the Losartan drug was 25% with a p-value of 0.001. The graph shows the study months and the percentage of patients with stroke over time.*

This is a table with data on the primary endpoint events, including stroke, observed during a study on two drugs, Losartan potassium tablets and Atenolol, across different demographic subgroups. The subgroups include age, gender, race, IsH (hypertension), diabetes, and history of CVD (cardiovascular disease). The results report the number of patients, the rate of events, hazard ratio, and 95% confidence interval. The table shows Losartan potassium tablets are favored in some subgroups, while Atenolol is favored in others. The symbols represent a proportional sample size. "Other" includes Asian, Hispanic Asiatic, Multace, Indian, Native American, and European. The data is adjusted for baseline Framingham risk score and electrocardiographic ventricular hypertrophy.*

This appears to be data from a clinical trial comparing the effects of Losartan Potassium Tablets to a placebo medication. The image shows a graph with percentages of patients experiencing an event (not specified) over a period of time (not specified) for both groups. The graph suggests that the Losartan Potassium Tablets group had a lower percentage of patients experiencing the event compared to the placebo group. The text also indicates a risk reduction of 16.1% and a p-value of 0.022. However, without further information, it is not possible to determine the specific medical condition being studied or the significance of these findings.*